Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 trial to evaluate the activity of sorafenib in relapsed or refractory CLL
patients with an iwCLL-WG indication to receive therapy.
Sorafenib is an orally active multikinase inhibitor, which targets the RAF/MEK/ERK signaling
pathway as well as several receptor tyrosine kinases. It is FDA approved for the treatment of
hepatocellular carcinoma and renal cell carcinoma. Preclinical studies in the investigators
laboratory demonstrated that sorafenib is cytotoxic to CLL cells.
The primary objective of the study is to determine the overall response rate of Sorafenib in
previously treated CLL patients. All patients will receive sorafenib at 400 mg twice daily
continuously for three months and then assessed for response. Responding patients may elect
to continue on treatment for an additional 9 months.